HSDT - heliusmedical.com Debt to Book Capitalization Ratio

Corporate company logo of Helius Medical Technologies Inc. (HSDT)

Demand for neurorehabilitation remains stable regardless of market cycles, yet the automated production of stimulators requires a precise capacity utilization plan. In GURU.Markets, the ratio of balance sheet capital coverage by total debt resolves this contradiction, where the value of 0.00 reflects the metric's balance between risk and growth. Geopolitical barriers and microelectronics supply chain challenges continue to constrain the ultimate success of Helius Medical (HSDT).

Helius Medical Technologies (HSDT) - Debts to Book Value from 07/04/2022 to 10/27/2026
Flagship merchandise of Helius Medical Technologies

To objectively assess the operational success of Helius Medical (HSDT), it is necessary to analyze its financing structure. The debt-to-equity ratio, reflecting the company's current share of debt in its book capitalization, measures the level of financial leverage. An increase in this ratio signals heightened credit risk, while a decrease indicates a conservative approach. An optimal balance of borrowings allows for the effective scaling of Inertia neurostimulators' implementation into clinical practice. A stable revenue stream from device rentals must ensure debt service without the threat of default.

Competitors of Helius Medical (HSDT)

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|VKTX - Debts to Book Capitalization|Debt to Net Assets Ratio supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value DNLI (Denali)|Debt to Book Capitalization Ratio Harmony Pharma HRMY|Debt to Book Capitalization Ratio Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|trevitherapeutics.com (TRVI) - Debts to Net Assets|PRAX: Debt to Book Value|AVXL (Anavex) - Debts to Book Capitalization|CBLL: Debt to Book Capitalization Ratio|Debts to Net Assets prothena.com (PRTA)|Alector, Inc. (ALEC) - Debt to Book Value|Debt to Net Assets Ratio ANNX (annexonbio.com)|Omeros - Debt to Book Capitalization Ratio|Debt to Book Value Neurogene Inc NGNE|ACIU (AC Immune Corp) - Debts to Book Capitalization|VYGR - Debts to Book Value|Debts to Book Capitalization Neumora Therapeutics|scilexholding.com (SCLX) - Debt to Book Value Ratio|TVGN: Debts to Book Capitalization|Debts to Net Assets Alpha Cognition Corp|Debts to Book Capitalization CGTX (Cognition Therapeutics)|Debt to Book Value Inhibikase Pharma (IKT)|Debts to Book Capitalization SAVA (Cassava Sciences, Inc.)|Assertio Holdings - Debts to Book Capitalization|COYA - Debt to Book Capitalization Ratio|VTGN - Debt to Book Capitalization Ratio|Debts to Book Capitalization ovidrx.com OVID|ABOS (Acumen Pharmaceuticals, Inc) - Debt to Net Assets Ratio|CRVO: Debt to Book Capitalization Ratio|Debts to Net Assets Alterity Therapeutics Ltd|Debts to Book Capitalization Clene Inc. CLNN|Debt to Book Value Ratio pepgen.com PEPG|Debt to Book Value Jupiter Neurosciences Inc (JUNS)|Relmada Corp - Debt to Book Capital|Annovis Bio, Inc. (ANVS) - Debt to Book Capitalization Ratio|GRCE - Debt to Book Value Ratio|Debts to Book Capitalization AIFF|Debts to Book Value Klotho Neurosciences|NRSN (NeuroSense Therapeutics Ltd) - Debt to Book Value|Debts to Book Capitalization RVPH|MetaVia Inc (MTVA) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NRXS (neuraxis.com)|PASG: Debt to Book Capitalization Ratio|Debts to Book Value Neuphoria Therapeutics, Inc. NEUP|Debts to Book Capitalization Minerva Neurosciences Corp (NERV)|ATHA - Debt to Net Assets Ratio|Debts to Book Capitalization ADXN|ALZN (Alzamend Neuro) - Debts to Book Value|Debt to Book Capitalization Ratio Cyclerion Therapeutics Inc.|Debt to Book Capitalization Ratio Protagenic|KTTA (Pasithea Therapeutics) - Debts to Book Capitalization|Debts to Net Assets cortigent.com CRGT|Debt to Book Value ATXI (Avenue Therapeutics)|brainstorm-cell.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio CARA (Cara Therapeutics)|Chromocell Therapeutics Corp (CHRO) - Debts to Net Assets|Debt to Book Value eliemtx.com ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio LBPH|Debt to Book Value marinuspharma.com|NKGen Biotech - Debts to Book Capitalization|Debts to Book Value NeuroBo Pharmaceuticals Inc (NRBO)|SAGE - Debts to Book Capitalization|Debt to Book Value Ratio Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|VIGL - Debts to Net Assets|WENA (Anew Medical) - Debts to Book Capitalization|Cerevel Therapeutics Inc (CERE) - Debt to Book Value